MediciNova shares surge 12.86% after-hours after winning BioTech Breakthrough Award for ALS drug development.

MediciNova surged 12.86% in after-hours trading following its recognition as a winner of the "Contract Research and Development Innovation Award" at the 2025 BioTech Breakthrough Awards. The award highlighted the company’s progress with MN-166 (ibudilast), a lead candidate in Phase 3 trials for ALS and DCM, emphasizing its potential as a disease-modifying therapy for neurodegenerative conditions. The CEO noted the award underscores the team’s commitment to addressing unmet medical needs, reinforcing confidence in the ongoing COMBAT-ALS trial and future development milestones. The accolade, presented by a prominent market intelligence organization, validated MediciNova’s innovative pipeline and positioned the stock for renewed investor interest amid its focus on advancing therapies with significant market potential.